Top 5 Deals Of 2022: The Economic Drag On M&A Continues
Executive Summary
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.
You may also be interested in...
2022 Deal-Making Snapshot: One Big Deal Didn’t Change The Downward Trends
Even with Amgen’s $27.8bn acquisition of Horizon in mid-December, biopharma M&A volume, total value and average deal value all dropped substantially from 2021.
Pfizer-gen? Pfizer Is The Latest Rumored Suitor For Seagen
Pfizer and Seagen reportedly are in merger discussions, signaling Pfizer’s willingness to invest significantly in antibody-drug conjugates (ADCs) for cancer.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.